Novel FGF homologs
AssigneeZymoGenetics, Inc.
InventorsTheresa A. Deisher, Darrell C. Conklin
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of using zFGF5 compositions to proliferate chondrocytes and their progenitors, and to induce deposition of cartilage. zFGF5 compositions are disclosed for treating disorders associated with chondrocytes, such as cartilage injuries and defects. In addition, methods for treating neurological disorders, such as stroke, are disclosed, and methods for using zFGF5 compositions to stimulate growth of cells associated with neurological injury and disease are disclosed.
Claims12
A method of reducing infarct volume in a mammal diagnosed as having a cerebrovascular ischemic stroke comprising:
- (1) determining infarct volume in the mammal;
- (2) administering a pharmaceutical composition comprising a polypeptide that is at least 80% identical to an amino acid sequence as shown in SEQ ID NO:
- 2 from amino acid residue 28 (Glu) to amino acid residue 175 (Met) sufficient to reduce infarct volume;
- (3) determining infarct volume in the mammal;
- and
- (4) comparing the infarct volume of step 1 to step 4.
A method for treating a patient who has suffered an injury to the central nervous system, comprising administering to the patient a pharmaceutical composition comprising a fibroblast growth factor (FGF) homolog polypeptide, wherein said polypeptide comprises a sequence of amino acids that is at least 80% identical to the amino acid sequence as shown in SEQ ID NO:
- 2 from amino acid residue 28 (Glu) to 175 (Met), in amount sufficient to improve functional recovery in the patient.
A method of increasing cartilage deposition in a patient comprising:
- administering a pharmaceutical composition comprising a fibroblast growth factor (FGF) homolog polypeptide to a fibrocartilage, hyaline, or elastic cartilage injury in said patient, wherein said polypeptide comprises a sequence of amino acids that is at least 80% identical to the amino acid sequence as shown in SEQ ID NO:
- 2 from amino acid residue 28 (Glu) to 175 (Met).
Dependencies are inferred from the claim text.